Medinet, Two Medical Institutions Jointly Launch Clinical Studies of Gamma-delta T Cell Therapy for Multiple Myeloma.Tokyo, Japan, Dec 7, 2005 - (JCN JCN Japan Corporate NewsJCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Japanese contract research organization (CRO) Medinet has signed a joint research agreement with two medical institutions, the Japanese Red Cross Medical Center and the Shin-Yokohama Medical Clinic. The three partners will jointly undertake through March 2006 clinical studies of lymphokine-activated killer cell In cell biology, a lymphokine-activated killer cell (also known as a LAK cell) is a white blood cell that has been stimulated to kill tumour cells.[1] If lymphocytes are cultured in the presence of Interleukin 2, it results in the development of effector cells therapy using gamma-delta T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. . Specifically, they aim to verify the safety and validity of cell therapy in treating multiple myeloma, a type of blood cancer that develops anemia, renal damage, bone pain and fracture, and hypercalcemia Hypercalcemia Definition Hypercalcemia is an abnormally high level of calcium in the blood, usually more than 10.5 milligrams per deciliter of blood. . Medinet will provide raw data on the therapy to the institutions while analyzing results obtained from the clinical studies. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion